Posted by Michael Wonder on 18 Jul 2021
U.S. FDA grants priority review for the biologics license application for Pfizer-BioNTech COVID-19 vaccine
16 July 2021 - Pfizer and BioNTech today announced that the U.S. FDA granted priority review designation for the biologics license application for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older.
The Prescription Drug User Fee Act goal date for a decision by the FDA is in January 2022.
